SMOKE FREE SWEDEN: DANSKE RESTRIKTIONER PÅ NIKOTINPOSER VIL FÅ 150.000 TIL AT VENDE TILBAGE TIL RYGNING
6.10.2024 17:00:00 CEST | Business Wire | Pressemeddelelse
Et foreslået forbud mod ni ud af ti nikotinposer i Danmark vil være et massivt tilbageskridt i kampen mod tobak og vil tvinge titusindvis af tidligere rygere tilbage til dødelige cigaretter, advarer førende internationale eksperter i dag.
Reguleringer på sundhedsområdet, som vil blive fremlagt for Folketinget fredag den 11. oktober, vil begrænse nikotinniveauet i en nikotinpose til 9 mg – langt under internationale standarder og kun en brøkdel af nikotinniveauet i cigaretter.
Dr. Delon Human, en global ekspert i skadereduktion og leder af ”Smoke Free Sweden”, siger: "Nikotinposer er bevist at være et langt sikrere alternativ til cigaretter og hjælper millioner af rygere med at stoppe over hele verden.”
"Forslaget, som Folketinget skal behandle, vil forbyde 90 % af de poser, der aktuelt bruges i Danmark, hvilket efterlader rygerne med valget mellem de få tilbageværende poser eller cigaretter, der indeholder 85 % mere nikotin.
"Det er ikke svært at forudsige, hvilket valg de vil ende med at træffe. Rygere, der overvejer at stoppe, vil blive nægtet et levedygtigt og sikrere alternativ, mens størstedelen af de 153.000 nuværende brugere af nikotinposer vil blive presset tilbage til cigaretter.
"At gøre den farligste måde at indtage nikotin på til den mest attraktive er simpelthen ulogisk og et massivt tilbageskridt i den fortsatte kamp mod tobakkens dødelige konsekvenser."
Danmarks naboland Sverige har vist, at en progressiv tilgang til skadesreducerende røgfrie nikotinprodukter er den bedste vej til at udrydde rygning og de sundhedskonsekvenser, som følger med.
Sverige har oplevet et ekstraordinært fald i antallet af rygere på 55 % over det seneste årti og er på nippet til officielt at blive erklæret røgfrit efter WHO’s målsætning. Sammenlignet med resten af EU har Sverige nu 44 % færre tobaksrelaterede dødsfald og en 41 % lavere kræftrate.
Sveriges succes tilskrives den udbredte brug af orale nikotinprodukter med forskellige nikotinstyrker og smagsvarianter samt regeringens politik med at lægge højere afgifter på cigaretter end på røgfrie nikotinprodukter.
Det danske forslag har til hensigt at forbyde de lange cigaretter, som i øjeblikket bruges af en tredjedel af rygerne, samtidig med at nikotinindholdet i poser begrænses.
"Forbuddet mod 30 % af cigaretterne på markedet burde være en stor mulighed for at opmuntre rygere til at skifte til sikrere alternativer som nikotinposer," siger Dr. Human. "I stedet forsøger forslagene at gøre poser ineffektive og mindre tiltalende end cigaretter.
"Som i Sverige bør den danske regering anerkende den vigtige rolle, disse skadesreducerede nikotinprodukter spiller i at hjælpe rygere med at overgå fra røgtobak og gøre sikrere alternativer tilgængelige, acceptable og til at betale."
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20241006970721/da/
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
Galderma Tackles Menopause-related Skin Changes With Global Survey and Clinical Trial Inclusivity30.1.2026 07:00:00 CET | Press release
Results from a global survey of over 4,300 women across five continents presented at IMCAS 2026 reveal a knowledge gap on the impact of menopause on the skin, despite women experiencing around three skin changes during menopause1 Galderma will also host a symposium delving into the challenges and science behind menopause-related skin changes and aesthetic solutions at the congress Galderma is committed to raising awareness of the impact of menopause on the skin, fostering meaningful dialogue between patients and healthcare professionals, and advancing science-backed solutions by incorporating menopausal status into all injectable aesthetics clinical trials Galderma (SIX: GALD) has unveiled findings from a global survey of peri- and post-menopausal women from nine countries exploring the impact of menopause on the skin at the International Master Course on Aging Science (IMCAS) 2026 World Congress in Paris, France, from January 29-31, 2026. The survey found that over 50% of women learne
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum